RE:RE:RE:Sanofi Exploring Acquisition of KRAS Cancer Drugmaker MiratiOctober 31, 2023 - BMY today announced that it has priced a public offering (the “Offering”) of senior unsecured notes in a combined aggregate principal amount of $4.5 billion (collectively, the “Notes”). Bristol Myers Squibb intends to use the net proceeds of the Offering for general corporate purposes, including, but not limited to, the financing of the previously announced proposed acquisition of Mirati Therapeutics, Inc. (the “Acquisition”)
https://www.biospace.com/article/releases/bristol-myers-squibb-prices-4-5-billion-of-senior-unsecured-notes/